PROMISE Substudy Results, Published in the American Heart Journal, Provide Independent Validation of the Clinical Value of the Corus(R) CAD Blood Test to Accurately Identify Patients with Obstructive CAD - Seite 3

For an external point of view on the impact of the PROMISE substudy results from cardiologist Andrew Waxler, MD, FACC, Berks Cardiologists, Ltd., click here.

About Obstructive Coronary Artery Disease
Coronary artery disease (CAD) is a very common heart condition in the United States. One in seven deaths among Americans is caused by CAD.³ CAD can cause a narrowing or blockage of the coronary arteries (vessels to the heart that supply the heart with blood, oxygen, and nutrients), reducing blood flow to the heart muscle. This narrowing or blockage in the coronary arteries is often referred to as obstructive CAD, characterized by the presence of atherosclerosis, or plaque.

About the PROMISE Trial
Sponsored by Duke University in collaboration with the National Heart Lung and Blood Institute (NHLBI) the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) is the first large randomized trial using clinical outcomes to compare alternative diagnostic strategies for assessment of patients with new stable symptoms suggestive of coronary artery disease (CAD).⁴

As part of the trial, a genomic archive of blood samples from study patients was obtained which included genetic material (DNA), genomic material (RNA) and plasma. CardioDx purified and isolated DNA and RNA using proprietary methods. In addition, the company's Corus CAD blood test was used to evaluate blood samples from an estimated 2,500 to 3,000 non-diabetic patients enrolled in the trial, with the goal of determining the test's ability to predict major clinical cardiovascular events.

About the Corus CAD Test
Corus CAD is the first and only commercially available blood test that can safely and conveniently help primary care clinicians and cardiologists assess whether or not a stable non-diabetic patient's symptoms may be due to obstructive coronary artery disease. The test incorporates age, sex and gene expression measurements into a single score that indicates the likelihood of obstructive CAD. Clinicians use the Corus CAD score, along with other clinical information, to determine whether further cardiac testing is necessary, which can help patients avoid unnecessary exposure to radiation associated with medical imaging testing, as well as possible reactions to imaging dyes and/or potential complications from invasive cardiac tests requiring catheterization. The test involves a routine blood draw that is conveniently administered in the clinician's office or clinical laboratory patient service center. The Corus CAD test is the only sex-specific test for the evaluation of obstructive CAD because it accounts for cardiovascular differences between men and women.